These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 21567082)

  • 1. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
    Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
    Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
    Kobayashi H; Hashiguchi Y; Ueno H; Shinto E; Kajiwara Y; Mochizuki H
    Dis Colon Rectum; 2007 Sep; 50(9):1354-62. PubMed ID: 17308999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
    Ma Y; Zhang P; Wang F; Zhang H; Yang J; Peng J; Liu W; Qin H
    Gut; 2012 Oct; 61(10):1447-53. PubMed ID: 22052060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy.
    Ko MA; Zehong G; Virtanen C; Guindi M; Waddell TK; Keshavjee S; Darling GE
    Ann Thorac Surg; 2012 Oct; 94(4):1094-102; discussion 1102-3. PubMed ID: 22939244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
    Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
    Gao W; Yu Y; Cao H; Shen H; Li X; Pan S; Shu Y
    Biomed Pharmacother; 2010 Jul; 64(6):399-408. PubMed ID: 20363096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
    Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
    Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer.
    Perez RO; São Julião GP; Habr-Gama A; Kiss D; Proscurshim I; Campos FG; Gama-Rodrigues JJ; Cecconello I
    Dis Colon Rectum; 2009 Jun; 52(6):1137-43. PubMed ID: 19581858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
    Caramés C; Cristobal I; Moreno V; Marín JP; González-Alonso P; Torrejón B; Minguez P; Leon A; Martín JI; Hernández R; Pedregal M; Martín MJ; Cortés D; García-Olmo D; Fernández MJ; Rojo F; García-Foncillas J
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
    Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
    Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
    Svoboda M; Sana J; Fabian P; Kocakova I; Gombosova J; Nekvindova J; Radova L; Vyzula R; Slaby O
    Radiat Oncol; 2012 Nov; 7():195. PubMed ID: 23167930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.